<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR941202-0-00035</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4700 -->  <!-- PJG ITAG l=80 g=1 f=1 --> &sect;35.615 <!-- PJG /ITAG -->  <!-- PJG ITAG l=89 g=1 f=1 --> Safety precautions.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=37 g=1 f=1 --> * * * * *  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (d) *&blank;*&blank;*  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (3) A radiation monitor must be checked with a dedicated check source for proper operation each day before the teletherapy unit is used for treatment of patients or human research subjects.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=37 g=1 f=1 --> * * * * *  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (e) A licensee shall construct or equip each teletherapy room to permit continuous observation of the patient or the human research subject from the teletherapy unit console during irradiation.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 42. In &sect;35.900, paragraphs (a)(4) and (a)(5) are revised and paragraphs (a)(6) through (a)(9) are added to read as follows:  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=80 g=1 f=1 --> &sect;35.900 <!-- PJG /ITAG -->  <!-- PJG ITAG l=89 g=1 f=1 --> Radiation Safety Officer.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=37 g=1 f=1 --> * * * * *  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (a) *&blank;*&blank;*  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (4) American Board of Science in Nuclear Medicine;  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (5) Board of Pharmaceutical Specialties in Nuclear Pharmacy;  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (6) American Board of Medical Physics in radiation oncology physics;  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (7) Royal College of Physicians and Surgeons of Canada in nuclear medicine;  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (8) American Osteopathic Board of Radiology; or  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (9) American Osteopathic Board of Nuclear Medicine; or  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=37 g=1 f=1 --> * * * * *  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 43. In &sect;35.910, paragraph (a)(3) is revised, paragraphs (a)(4) and (a)(5) are added, and paragraphs (b)(2)(i), (b)(2)(iii), and (b)(2)(v) are revised to read as follows:  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=80 g=1 f=1 --> &sect;35.910 <!-- PJG /ITAG -->  <!-- PJG ITAG l=89 g=1 f=1 --> Training for uptake, dilution, and excretion studies.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=37 g=1 f=1 --> * * * * *  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (a) *&blank;*&blank;*  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (3) Diagnostic radiology or radiology by the American Osteopathic Board of Radiology;  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (4) Nuclear medicine by the Royal College of Physicians and Surgeons of Canada; or  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (5) American Osteopathic Board of Nuclear Medicine in nuclear medicine; or  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (b) *&blank;*&blank;*  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (2) *&blank;*&blank;*  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (i) Examining patients or human research subjects and reviewing their case histories to determine their suitability for radioisotope diagnosis, limitations, or contraindications;  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=37 g=1 f=1 --> * * * * *  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (iii) Administering dosages to patients or human research subjects and using syringe radiation shields;  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=37 g=1 f=1 --> * * * * *  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (v) Patient or human research subject followup; or  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=37 g=1 f=1 --> * * * * *  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 44. In &sect;35.920, paragraphs (a)(2) and (a)(3) are revised, paragraphs (a)(4) and (a)(5) are added, and paragraphs (b)(2)(iii), (b)(3)(i), (b)(3)(iii), and (b)(3)(v) are revised to read as follows:  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=80 g=1 f=1 --> &sect;35.920 <!-- PJG /ITAG -->  <!-- PJG ITAG l=89 g=1 f=1 --> Training for imaging and localization studies.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=37 g=1 f=1 --> * * * * *  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (a) *&blank;*&blank;*  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (2) Diagnostic radiology by the American Board of Radiology;  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (3) Diagnostic radiology or radiology by the American Osteopathic Board of Radiology;  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (4) Nuclear medicine by the Royal College of Physicians and Surgeons of Canada; or  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (5) American Osteopathic Board of Nuclear Medicine in nuclear medicine; or  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (b) *&blank;*&blank;*  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (2) *&blank;*&blank;*  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (iii) Calculating and safely preparing patient or human research subject dosages;  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=37 g=1 f=1 --> * * * * *  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (3) *&blank;*&blank;*  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (i) Examining patients or human research subjects and reviewing their case histories to determine their suitability for radioisotope diagnosis, limitations, or contraindications;  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=37 g=1 f=1 --> * * * * *  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (iii) Administering dosages to patients or human research subjects and using syringe radiation shields;  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            